Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction

作者：Heading Christine E^*

来源：Current Opinion in Investigational Drugs, 2007, 8(1): 71-77.

Cytos Biotechnology AG is developing an intramuscular therapeutic vaccine, CYT-002-NicQb ( also known as nicotine-Q beta), based on its Immunodrug ( formerly known as alpha vaccine) nicotine-specific antibody-generating technology, for the potential treatment of nicotine addiction. A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007.

• 出版日期2007-1